COVID-19 Thrombosis
Cross-source consensus on COVID-19 Thrombosis from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Risks & contraindications
Evidence quality
Highlighted claims
- COVID-19 produces a hypercoagulable state significantly beyond typical hospital-acquired thrombosis risk. — COVID-19: Evidence Hierarchy, ICU Management, and Emerging Treatments
- D-dimer values in severe COVID-19 can reach 35 mg/L, which is 70 times the upper limit of normal. — COVID-19: Evidence Hierarchy, ICU Management, and Emerging Treatments
- Supplemental vitamin K is counterproductive for COVID-19 patients concerned about clot risk because it pushes the coagulation system toward hypercoagulability. — COVID-19: Evidence Hierarchy, ICU Management, and Emerging Treatments
- An autopsy series found nine times the normal number of micro-clots in the pulmonary vasculature of COVID-19 decedents. — COVID-19: Evidence Hierarchy, ICU Management, and Emerging Treatments
- No published consensus protocol exists for when to escalate COVID-19 patients to therapeutic anticoagulation doses. — COVID-19: Evidence Hierarchy, ICU Management, and Emerging Treatments